Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCAR-019 in CD19+ Relapsed or Refractory Leukemia and Lymphoma
NCT02819583Phase 2Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Oct 2016
- Primary completion
- Sep 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of PCAR-019 in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), B-cell prolymphocytic leukemia (B-PLL), sponsored by PersonGen BioTherapeutics. Status: unknown.
02
Drugs
PCAR-019
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)B-cell prolymphocytic leukemia (B-PLL)
Beyond the preview
Go deeper on NCT02819583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819583.